Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2004 Oct 18:(4):CD004371.
doi: 10.1002/14651858.CD004371.pub2.

Interventions to improve adherence to lipid lowering medication

A Schedlbauer  1 , K Schroeder, T J Peters, T Fahey
Affiliations
Meta-Analysis

Interventions to improve adherence to lipid lowering medication

A Schedlbauer et al. Cochrane Database Syst Rev. .

Update in

Abstract

Background: Lipid lowering drugs are still widely underused, despite compelling evidence about their effectiveness in the treatment and prevention of cardiovascular disease. Poor patient adherence to medication regimen is a major factor in the lack of success in treating hyperlipidaemia. In this review we focus on interventions, which encourage patients at risk of heart disease or stroke to take lipid lowering medication regularly.

Objectives: To assess the effect of interventions aiming at improved adherence to lipid lowering drugs, focusing on measures of adherence and clinical outcomes.

Search strategy: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, PsycInfo and CINAHL. Date of most recent search was in February 2003. No language restrictions were applied.

Selection criteria: Randomised controlled trials of adherence-enhancing interventions to lipid lowering medication in adults for both primary and secondary prevention of cardiovascular disease in an ambulatory setting.

Data collection and analysis: Two reviewers extracted data independently and assessed studies according to criteria outlined by the Cochrane Reviewers' Handbook.

Main results: The eight studies found contained data on 5943 patients. Interventions could be stratified into four categories : 1. simplification of drug regimen, 2. patient information/education, 3. intensified patient care such as reminding and 4. complex behavioural interventions such as group sessions. Change in adherence ranged from -3% to 25% (decrease in adherence by 3% to increase in adherence by 25%). Three studies reported significantly improved adherence through simplification of drug regimen (category 1), improved patient information/education (category 2) and reminding (category 3). The fact that the successful interventions were evenly spread across the categories, does not suggest any advantage of one particular type of intervention. The methodological and analytical quality was generally low and results have to be considered with caution. Combining data was not appropriate due to the substantial heterogeneity between included randomised controlled trials (RCTs).

Reviewers' conclusions: At this stage, no specific intervention aimed at improving adherence to lipid lowering drugs can be recommended. The lack of a gold standard method of measuring adherence is one major barrier in adherence research. More reliable data might be achieved by newer methods of measurement, more consistency in adherence assessment and longer duration of follow-up. Increased patient-centredness with emphasis on the patient's perspective and shared-decision-making might lead to more conclusive answers when searching for tools to encourage patients to take lipid lowering medication.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

    1. Brown BG, Bardsley J, Poulin D, Hillger LA, Dowdy A, Maher VM, et al. Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg/dl in patients with hyperlipidemia and coronary artery disease. American Journal of Cardiology. 1997;80(2):111–5. - PubMed
    1. Faulkner MA, Wadibia EC, Lucas BD, Hilleman DE. Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial. Pharmacotherapy. 2000;20(4) - PubMed
    1. Guthrie RM. The effects of postal and telephone reminders on compliance with pravastatin therapy in a national registry: results of the first myocardial infarction risk reduction program. Clinical Therapeutics. 2001;23(6):970–80. - PubMed
    1. Marquez CE, Casado-Martinez JJ, Lopez dA, Cores PE, Lopez-Zamorano JM, Moreno-Garcia JP, et al. Therapeutic compliance in dyslipidemias. A trial of the efficacy of health education. Atencion Primaria. 1998;22(2):79–84. - PubMed
    1. Poston J, Loh E, Dunham W. The medication use study. Canadian Pharmaceutical Journal. 1998;131(10):31–8.

References to studies excluded from this review

    1. Allen JK. Cholesterol management: an opportunity for nurse case managers. Journal of Cardiovascular Nursing. 2000;14(2):50–8. - PubMed
    1. Allen JK, Blumenthal RS, Margolis S, Rohm YD, Miller ER, III, Kelly K. Nurse case management of hypercholesterolemia in patients with coronary heart disease: Results of a randomized clinical trial. American Heart Journal. 2002;144(4):678–86. - PubMed
    1. Alvarez MS, Gomez de la Fuente FJ, Gallego CP, Picon Garcia dL. Effectuve strategies to improve adherence to drug prescription. Medifam - Revista de Medicina Familiar y Comunitaria. 2001;11(8):467–71.
    1. Anonymous Pharmacist-managed lipid program reduces medication costs despite increase in drug utilization. Hospital Formulary. 2001;36(5):378–80.
    1. Anonymous Risk factors for CHD not being identified. British Journal of Cardiology. 2001;8(6):356–8.

References to ongoing studies

    1. Improved compliance and persistence with atorvastatin through a pharmacy -based intervention. Ongoing study not reported

Additional references

    1. Scandinavian Simvastatin, Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet. 1994;344(8934):1383–9. - PubMed
    1. Alderson P, Green S, Higgins JPT, editors. [accessed 31st January 2004];Section 6 Assessment of study quality. Cochrane Reviewers’ Handbook 4.2.2 [updated December 2003] http://www.cochrane.org/resources/handbook/hbook.htm
    1. Assmann SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet. 2000;355(9209):1064–9. - PubMed
    1. Athyros VG, Papageorgiou AA, Mercouris BR, Athyrou VV, Symeonidis AN, Basayannis EO, et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus ‘usual’ care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Current Medical Research & Opinion. 2002;18(4):220–8. - PubMed
    1. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (ATP III) Third Report of the National Cholesterol Education Program (NCEP) http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3xsum.pdf. - PubMed

MeSH terms

Substances